UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended June 30, 2022
☐
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from to
Commission
File No. 333-188920
SCOUTCAM
INC.
(Exact
name of registrant as specified in its charter)
Nevada
47-4257143
(State
or other jurisdiction
of
incorporation or organization)
(I.R.S.
Employer
Identification
No.)
Suite
7A , Industrial Park
P.O.
Box 3030 , Omer , Israel
8496500
(Address
of Principal Executive Offices)
(Zip
Code)
+972
73 370-4691
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of exchange on which registered
N/A
N/A
N/A
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
☐
Large
accelerated filer
☐
Accelerated
filer
☒
Non-accelerated
filer
☒
Smaller
reporting company
☐
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As
of August 11, 2022, the registrant had 7,121,737 shares of common stock, par value $0.001, of the registrant issued and outstanding.
As
used in this Quarterly Report and unless otherwise indicated, the terms “ScoutCam,” “we,” “us,” “our,”
or “our Company” refer to ScoutCam Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars.
SCOUTCAM
INC.
QUARTERLY
REPORT ON FORM 10-Q
TABLE
OF CONTENTS
Page
Cautionary Note Regarding Forward-Looking Statements
3
PART
1-FINANCIAL INFORMATION
Item
1.
Consolidated Financial Statements (unaudited)
4
Consolidated Balance Sheets
5
Consolidated Statements of Comprehensive Loss
7
Statements of Stockholders’ Equity
8
Consolidated Statements of Cash Flows
10
Notes to Consolidated Financial Statements
12
Item
2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
20
Item
3.
Quantitative and Qualitative Disclosures about Market Risk
26
Item
4.
Control and Procedures
26
PART
II-OTHER INFORMATION
Item
1A.
Risk Factors
27
Item
6.
Exhibits
27
SIGNATURES
28
- 2 -
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain
information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and
as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity,
financial condition, prospects and opportunities and are based upon information currently available to us and our management and their
interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events.
Forward-looking
statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use
of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,”
“anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project”
or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity,
financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those
expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements
may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2021 (filed on March 30, 2022) entitled
“Risk Factors” as well as in our other public filings.
In
light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the
forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements.
Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, changed circumstances or any other reason.
- 3 -
Item
1. Financial Statements
ScoutCam
INC.
INTERIM
FINANCIAL STATEMENTS
AS
OF JUNE 30, 2022
CONSOLIDATED
SCOUTCAM INC.
Page
Interim
Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands
Interim Condensed Consolidated Balance Sheets (unaudited)
5
Interim Condensed Consolidated Statements of Operations (unaudited)
7
Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)
8
Interim Condensed Consolidated Statements of Cash Flows (unaudited)
10
Notes to the Interim Condensed Consolidated Financial Statements
12
- 4 -
SCOUTCAM
INC.
INTERIM
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30,
December 31,
2022
2021
Unaudited
Audited
USD in thousands
Assets
CURRENT ASSETS:
Cash and cash equivalents
7,314
8,581
Short terms deposits
9,536
11,013
Accounts receivable
99
8
Inventory
609
167
Other current assets
410
443
Total current assets
17,968
20,212
NON-CURRENT ASSETS:
Contract fulfillment assets
1,615
1,675
Property and equipment, net
720
781
Operating lease right-of-use assets
431
482
Severance pay asset
329
396
Total non current assets
3,095
3,334
TOTAL ASSETS
21,063
23,546
The
accompanying notes are an integral part of these interim condensed consolidated financial statements.
- 5 -
SCOUTCAM
INC.
INTERIM
CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
June 30,
December 31,
2022
2021
Unaudited
Audited
USD in thousands
Liabilities and shareholders’ equity
CURRENT LIABILITIES:
Accounts payables
309
103
Contract liabilities - short term
1,426
346
Operating lease liabilities - short term
228
256
Accrued compensation expenses
376
355
Related parties
22
39
Other accrued expenses
295
210
Total current liabilities
2,656
1,309
NON-CURRENT LIABILITIES:
Contract liabilities - long term
2,429
2,074
Operating lease liabilities - long term
137
203
Liability for severance pay
328
344
Total non
current liabilities
2,894
2,621
TOTAL LIABILITIES
5,550
3,930
SHAREHOLDERS’ EQUITY:
Common stock, $ 0.001 par value; 300,000,000 shares authorized as of June 30, 2022 and December 31, 2021, 7,121,737 shares issued and outstanding as of June 30, 2022 and December 31, 2021
7
7
Additional paid-in capital
36,360
34,903
Accumulated deficit
( 20,854 )
( 15,294 )
TOTAL SHAREHOLDERS’ EQUITY
15,513
19,616
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
21,063
23,546
The
accompanying notes are an integral part of these interim condensed consolidated financial statements.
- 6 -
SCOUTCAM
INC.
INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
2022
2021
2022
2021
Six months ended
Three months ended
June 30,
June 30,
2022
2021
2022
2021
Unaudited
USD in thousands (except per share data)
Revenues
372
298
370
274
Cost of revenues
849
610
561
407
Gross Loss
( 477 )
( 312 )
( 191 )
( 133 )
Research and development expenses
1,975
643
1,021
362
Sales and marketing expenses
446
404
203
207
General and administrative expenses
2,452
2,328
1,166
1,395
Operating loss
( 5,350 )
( 3,687 )
( 2,581 )
( 2,097 )
Other income
15
-
7
-
Financing income (expenses), net
( 225 )
( 7 )
( 198 )
9
Net Loss
( 5,560 )
( 3,694 )
( 2,772 )
( 2,088 )
Net loss per ordinary share (basic and
diluted, USD)
( 0.78 )
( 0.67 )
( 0.39 )
( 0.31 )
Weighted average ordinary shares (basic
and diluted, in thousands)
7,122
5,480
7,122
6,724
- 7 -
SCOUTCAM
INC.
INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
Six
Months Ended June 30, 2022 (Unaudited)
Number
Amount
capital
deficit
Equity
Ordinary shares
Additional
paid-in
Accumulated
Total
Shareholders’
Number
Amount
capital
deficit
Equity
In thousands
USD in thousands
Balance at January 1, 2022
7,122
7
34,903
( 15,294 )
19,616
Stock based compensation
-
-
1,457
-
1,457
Net loss
-
-
-
( 5,560 )
( 5,560 )
Balance at June 30, 2022
7,122
7
36,360
( 20,854 )
15,513
Three
Months Ended June 30, 2022 (Unaudited)
Ordinary shares
Additional
paid-in
Accumulated
Total
Shareholders’
Number
Amount
capital
deficit
Equity
In thousands
USD in thousands
Balance at April 1, 2022
7,122
7
35,675
( 18,082 )
17,600
Stock based compensation
-
-
685
-
685
Net loss
-
-
-
( 2,772 )
( 2,772 )
Balance at June 30, 2022
7,122
7
36,360
( 20,854 )
15,513
The
accompanying notes are an integral part of these interim condensed consolidated financial statements.
- 8 -
Six
Months Ended June 30, 2021 (Unaudited)
Ordinary shares
Additional
paid-in
Accumulated
Total
Shareholders’
Number
Amount
capital
deficit
equity
In thousands
USD in thousands
Balance at January 1, 2021
4,084
4
10,267
( 6,307 )
3,964
Issuance of shares and warrants
2,469
2
19,116
-
19,118
Stock based compensation
-
-
635
-
635
Exercise of warrants
375
1
2,458
-
2,459
Net loss
-
-
-
( 3,694 )
( 3,694 )
Balance at June 30, 2021
6,928
7
32,476
( 10,001 )
22,482
Three
Months Ended June 30, 2021 (Unaudited)
Ordinary shares
Additional
paid-in
Accumulated
Total
Shareholders’
Number
Amount
capital
deficit
Equity
In thousands
USD in thousands
Balance at April 1, 2021
6,699
7
30,242
( 7,913 )
22,336
Exercise of warrants
229
*
1,678
-
1,678
Stock based compensation
-
-
556
-
556
Net loss
-
-
-
( 2,088 )
( 2,088 )
Balance at June 30, 2021
6,928
7
32,476
( 10,001 )
22,482
*
Represents
an amount less than $1 thousand
- 9 -
SCOUTCAM
INC.
INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
2022
2021
2022
2021
Six months ended
Three months ended
June 30,
June 30,
2022
2021
2022
2021
Unaudited
USD in thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
( 5,560 )
( 3,694 )
( 2,772 )
( 2,088 )
Adjustments to reconcile net loss to net cash used in operations:
Depreciation
103
39
53
22
Changes in severance pay asset, net
51
( 56 )
51
( 56 )
Share based compensation
1,457
635
685
556
Profit from exchange differences from operating lease liability
( 50 )
-
( 40 )
-
Loss (Profit) from exchange differences on cash and cash equivalents
327
( 4 )
286
( 16 )
Interest income in respect of deposits
( 23 )
-
( 10 )
-
CHANGES IN OPERATING ASSET AND LIABILITY ITEMS:
Increase in accounts receivable
( 91 )
( 43 )
( 85 )
( 49 )
Decrease (increase) in inventory
( 442 )
99
( 419 )
200
Decrease in operating lease liability
( 125 )
-
( 109 )
-
Decrease in ROU asset
132
113
-
Increase (decrease) in related parties
( 17 )
60
-
14
Decrease (increase) in other current assets
33
( 509 )
6
( 404 )
Increase (decrease) in account payables
206
224
82
( 189 )
Decrease (increase) in contract fulfillment assets
60
( 380 )
60
( 140 )
Increase (decrease) in contract liabilities
1,435
537
( 181 )
( 126 )
Increase in accrued compensation expenses
21
60
1
140
Increase (decrease) in other accrued expenses
85
( 22 )
105
( 144 )
Net cash flows used in operating activities
( 2,398 )
( 3,054 )
( 2,174 )
( 2,280 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
( 42 )
( 170 )
( 18 )
( 53 )
Withdrawal of short terms deposits
5,000
-
5,000
-
Investment in short term deposits
( 3,500 )
-
( 3,500 )
-
Net cash flows provided by (used in) investing activities
1,458
( 170 )
1,482
( 53 )
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants
-
2,504
-
1,723
Proceeds from issuance of shares and warrants
-
19,118
-
9,618
Net cash flows provided by financing activities
-
21,622
-
11,341
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
( 940 )
18,398
( 692 )
9,008
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS
( 327 )
4
( 286 )
16
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD
8,581
3,373
8,292
12,751
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD
7,314
21,775
7,314
21,775
- 10 -
Non
cash activities -
Six months ended
Three months ended
June 30,
June 30,
2022
2021
2022
2021
Unaudited
USD in thousands
Non cash activities
Issuance expenses
-
45
-
45
Right-of-use assets obtained
in exchange for operating lease liabilities
81
359
35
133
The
accompanying notes are an integral part of these interim condensed consolidated financial statements.
- 11 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – GENERAL :
a .
ScoutCam
Inc. (the “Company”), formerly known as Intellisense Solutions Inc., (“Intellisense”),
was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing
of the Exchange Agreement (as defined below), the Company was a non-operating “shell
company”.
The
Company’s wholly owned subsidiary, ScoutCam Ltd. (“ScoutCam”), was formed in the State of Israel on January 3,
2019, as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market,
and commenced operations on March 1, 2019.
In
December 2019, Medigus and ScoutCam consummated an asset transfer agreement, under which Medigus transferred and assigned certain
assets and intellectual property rights related to its miniaturized imaging business to ScoutCam.
On
December 30, 2019, Intellisense and Medigus consummated a securities exchange agreement (the “Exchange Agreement”), pursuant
to which Medigus delivered 100% of its holdings in ScoutCam to Intellisense in exchange for shares of Intellisense’s common
stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the consummation of the Exchange
Agreement.
As
of June 30, 2022, Medigus beneficially owned 27.01% of the Company’s outstanding common stock.
The
Company, through ScoutCam, provides image-based platforms. Through the use of its proprietary visualization technology, ScoutCam
offers solutions across predictive maintenance and condition-based monitoring markets, in sectors such as energy, automotive and
aviation. ScoutCam’s solutions are based on small and highly resilient cameras, specialized AI analysis and supplementary technologies.
- 12 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – GENERAL (continued):
b.
On
August 9, 2021, the Company amended its Articles of Incorporation to effect a nine-to-one reverse stock split of its outstanding
Common Stock. As a result of the reverse stock split, every nine shares of the Company’s outstanding Common Stock were combined
and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following
the reverse split. The amount of authorized capital of the Company’s Common Stock and par value of such shares remained unchanged.
All share, stock option and per share information in these interim consolidated financial statements have been adjusted to reflect
the reverse stock split on a retroactive basis.
c.
Since
incorporation of ScoutCam and through June 30, 2022, the Company accumulated a deficit of approximately $ 20,854 thousand and its activities
have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources as
of June 30, 2022 will enable the Company to fund its operating plan for more than 12 months from the date of issuance of these financial
statements. The Company expects to continue to incur significant research and development expenses and other costs related to its
ongoing operations and, as a result, will need to obtain additional funding in order to continue its future operations.
d.
In
early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID19) outbreak a pandemic. This
pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company considered
the impact of COVID-19 on its operations and determined that there were no material adverse impacts on the Company’s results
of operations and financial position as of June 30, 2022. These estimates may change, as new events occur and additional information
is obtained.
NOTE
2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
a.
Unaudited
Interim Financial Statements
The
accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting
principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities
and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair
presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information,
reference is made to the consolidated financial statements and footnotes thereto included in the Group’s Annual Report on Form
10-K for the year ended December 31, 2021.
b.
Principles
of Consolidation
The
accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany
balances and transactions have been eliminated in consolidation.
c.
Use
of estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its
assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock based compensation, as well as in
estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.
- 13 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):
d.
Significant
Accounting Policies
The
significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are
identical to those applied in the preparation of the latest annual financial statements.
As described therein, to the extent development services are not distinct from the performance obligation relating to the subsequent production
phase, revenue from these services is deferred until commencement of the production phase. Further to the inception of the production phase (refer to Note 5), the
Company recognizes deferred development services over the expected term of production.
e.
Recent
Accounting Pronouncements
Management
does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect
on the Group’s condensed consolidated financial statements.
NOTE
3 – LEASES :
On
June 30, 2022, the Group’s ROU assets and lease liabilities for operating leases totaled $ 431 thousands and $ 365 thousand, respectively.
In
December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning on
January 1, 2021. ScoutCam holds the right to terminate the lease agreement after 24 months. In March 2021, ScoutCam entered into a lease
agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. ScoutCam holds the right to terminate
these agreements by December 31, 2022 . Monthly lease payments under the agreements are approximately $ 12 thousand.
Lease
expenses recorded in the interim consolidated statements of operations were $ 136 thousand for the six months ended June 30, 2022.
ScoutCam
subleases part of the office space to a third party for approximately $ 3 thousand for month.
Supplemental
cash flow information related to operating leases was as follows:
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES
Six months ended
30, 2022
USD in thousands
Cash payments for operating leases
136
Total lease expenses
136
As
of June 30, 2022, the Company’s operating leases had a weighted average remaining lease term of 0.71 years and a weighted average
discount rate of 6 %. Future lease payments under operating leases as of June 30, 2022 were as follows:
SCHEDULE
OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES
Operating leases
USD in thousands
Remainder of 2022
122
2023
222
2024
41
Total future lease payments
385
Less imputed interest
( 20 )
Total lease liability balance
365
- 14 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
4 – EQUITY :
Warrants:
As
of June 30, 2022, the Company had the following outstanding warrants to purchase common stock:
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK
Warrant
Issuance Date
Expiration Date
Exercise Price
Per Share ($)
Number of Shares
of common stock
Underlying
Warrants
Warrant March 2021
March 29, 2021
March 31, 2026
10.350
2,469,156
2,469,156
In
addition, if ScoutCam achieves an aggregate amount of $ 33 million in sales within the first three years immediately after the Exchange
Agreement, the Company will issue to Medigus 298,722 shares of the Company’s common stock, which represents 10 % of the Company’s
issued and outstanding share capital as of the Exchange Agreement.
- 15 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
4 – EQUITY (continued):
Share-based
compensation to employees, directors and service providers:
In
February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”). The Plan initially
included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers.
On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan
by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the
Company’s option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021,
the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional
777,778 shares of common stock.
The
Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes
including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend
or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through
a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.
Stock
option activity
During
the six months ended June 30, 2022, the Company granted 53,000 options pursuant to the Plan.
The
fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option pricing model,
using the following assumptions:
SCHEDULE
OF SHARE-BASED PAYMENT, STOCK OPTIONS, VALUATION ASSUMPTIONS
Six months
ended
June 30, 2022
Underlying value of ordinary shares ($)
7.2
Exercise price ($)
4.5
Expected volatility (%)
127.62 %
Term of the options (years)
7
Risk-free interest rate
1.98 %
The
cost of the benefit embodied in the options granted during the six months ended June 30, 2022, based on their fair value as at the grant
date, is estimated to be approximately $ 356 thousands. These amounts will be recognized in statements of operations over the vesting
period.
- 16 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
4 – EQUITY (continued):
The
following table summarizes stock option activity for the six months ended June 30, 2022:
SCHEDULE
OF STOCK OPTIONS ACTIVITY
For the
Six months ended
June 30, 2022
Amount of
options
Weighted average
exercise price
$
Outstanding at beginning of period
1,253,554
3.31
Granted
53,000
4.50
Cancelled
( 37,011 )
2.61
Outstanding at end of period
1,269,543
4.14
Vested at end of period
673,509
2.98
Restricted
stock unit (“RSU”) activity
During
the six months ended June 30, 2022, the Company granted 90,000 RSUs pursuant to the Plan.
Each
RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized
as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the
date of grant based on the fair value of the Company’s common stock.
The
cost of the benefit embodied in the RSU granted during the six months ended June 30, 2022, based on their fair value as at the grant
date, is estimated to be approximately $ 648 thousands. These amounts will be recognized in statements of operations over the vesting
period
The
following table summarizes RSU activity for the six months ended June 30, 2022:
SCHEDULE
OF STOCK OPTIONS ACTIVITY
For the
Six months ended
June 30, 2022
Amount of
options
Weighted Average Grant Date Fair Value per Share
$
Outstanding at beginning of period
-
-
Granted
90,000
7.2
Vested
-
Forfeited
-
-
Unvested and Outstanding at end of period
90,000
7.2
- 17 -
SCOUTCAM
INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
4 – EQUITY (continued):
The
following table sets forth the total share-based payment expenses resulting from options granted, included in the statements of operation:
SCHEDULE OF TOTAL SHARE-BASED PAYMENT EXPENSES
Six months
ended
June 30, 2022
USD in thousands
Cost of revenues
48
Research and development
311
Sales and marketing
99
General and administrative
999
Total expenses
1,457
NOTE
5 – REVENUES :
Contract
fulfillment assets and Contract liabilities:
The
Company’s contract fulfillment assets and contract liabilities as of June 30, 2022 and December 31, 2021 were as follows:
SCHEDULE
OF CONTRACT LIABILITIES
June 30,
December 31,
2022
2021
USD in thousands
Contract fulfillment assets
1,615
1,675
Contract liabilities
3,855
2,420
Contract
liabilities include advance payments, which are primarily related to advanced billings for development services.
In the current quarter the Company completed the development service stage of its miniature camera solution relating these deferred development
services and moved from the development stage to the production stage. As a result, the Company recognized $ 106 thousands during the period,
based on the expected term of the production stage.
Remaining
Performance Obligations
Remaining
Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue
and amounts that will be recognized as revenue in future periods. As of June 30, 2022, the total RPO amounted to $ 3,855 thousand,
which the Company expects to recognize over the expected manufacturing term of the product under development.
- 18 -
NOTE
6 – SCOUTCAM INC.
NOTES
TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
6 - INVENTORY :
Composed
as follows:
SCHEDULE OF INVENTORY
June 30,
December 31,
2022
2021
USD in thousands
Raw materials and supplies
596
99
Work in progress
13
2
Finished goods
-
66
Inventory Net
609
167
During
the period ended June 30, 2022, no impairment occurred.
NOTE
7 – LOSS PER SHARE
Basic
loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company, by the weighted average number
of ordinary shares as described below.
In
computing the Company’s diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the
dilutive effect, if any, of the Company’s potential shares of common stock. The denominator for diluted loss per share is a computation
of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.
NOTE
8 – RELATED PARTIES
a. Balances with related parties :
SCHEDULE
OF BALANCES WITH RELATED PARTIES
June 30, 2022
December 31, 2021
USD in thousands
Directors(*)
22
-
Medigus
-
39
(*) represents directors’
compensation
b. During
six months ended June 30, 2022 the Company received development services from Smartec R&D
Ltd., a company owned by the Company’s CTO.
Total
compensation during the six months ended June 30, 2022 and June 30, 2021 was approximately $ 55 thousands and $ 40 thousands, respectively.
NOTE
9 – SUBSEQUENT EVENTS
On
July 12, 2022, the Company and the Chief Executive Officer of the Company, mutually agreed that the CEO’s employment with the
Company would terminate on October 18, 2022.
- 19 -
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Readers
are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial
statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2021. Some of the information
contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our
plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary
Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report for the
fiscal year ended December 31, 2021 for a discussion of important factors that could cause actual results to differ materially from the
results described in or implied by the forward-looking statements contained in the following discussion and analysis .
Overview
The
Company’s primary business activity during last few months was enlarging its focus on R&D activities in the domain of I4.0 (including
Predictive Maintenance, PdM, and Condition Based Monitoring, CBM, in sectors such as the aviation, energy and automotive). The main
effect of this activity was an increase in the number of employees to enable the Company to manage the anticipated increased workload
and solution development.
In addition,
recently the Company completed the verification and validation (V&V) stage of its miniature camera solution with a Fortune 500 company
and moved from R&D stage to production stage.
Comparison
of the six months ended June 30, 2022 and 2021
The
following table summarizes our results of operations for the six months period ended June 30, 2022 and 2021, together with the changes
in those items in dollars and as a percentage:
Six months ended June 30,
2022
2021
% Change
Revenues
372,000
298,000
25 %
Cost of Revenues
849,000
610,000
39 %
Gross Loss
(477,000 )
(312,000 )
53 %
Research and development expenses
1,975,000
643,000
207 %
Sales and marketing expense
446,000
404,000
10 %
General and administrative expenses
2,452,000
2,328,000
5 %
Operating Loss
(5,350,000 )
(3,687,000 )
45 %
Revenues
As
a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from
a limited number of customers.
For
the six months ended June 30, 2022, we generated revenues of $372,000, an increase of $74,000, or 25% from the six months ended June
30, 2021.
The increase in revenues was primarily due to the
increase in revenue from our miniature camera solution with the Fortune 500 company due to completion R&D stage and moving
to production stage. Total revenues recorded from o ur miniature camera solution with the
Fortune 500 company during the six months ended June 30, 2022, amounted to approximately $327,000.
We did not record any revenue from our miniature camera solution with the Fortune 500 company during
the six months ended June 30, 2021.
This increase in revenues was partly
offset by the following:
-
Total revenues recorded from A.M. Surgical during the six months ended June 30, 2021, amounted to approximately $200,000. We did not record any revenue from A.M. Surgical during the six months ended June 30, 2022.
-
the decrease of $53,000 d ue to an overall decrease in the sales of the Company’s component products to occasional customers.
Cost
of Revenues
Cost
of revenue is primarily comprised of cost of personnel including warehouse personnel costs, inventory write-downs, certain allocated
facilities and expenses associated with logistics and quality control.
Cost
of revenues for the six months ended June 30, 2022 was $849,000, an increase of $239,000, or 39%, compared to cost of revenues of $610,000
for the six months ended June 30, 2021. The increase was primarily due to an increase in materials as a result of an increase in revenues,
an increase in payroll expenses due to stock-based compensation and due to the transition from the R&D stage to the production stage
as described on “Overview” and increase in facility costs due to a lease for additional office space.
- 20 -
Gross
Loss
Gross
loss for the six months ended June 30, 2022 was $477,000, an increase of $165,000, or 53%, compared to gross loss of $312,000 for the
six months ended June 30, 2021.
The
increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.
Research
and Development Expenses
Research
and development efforts are focused on new product development and on developing additional functionality for our new and existing products.
These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for
personnel engaged in research and development functions, consulting and professional fees related to research and development activities,
prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities,
depreciation and other supplies. We expense research and development costs as incurred.
Research
and development expenses for the six months ended June 30, 2022 were $1,975,000, an increase of $1,332,000, or 207%, compared to $643,000
for the six months ended June 30, 2021.
The
increase was primarily due to an increase in payroll expenses (including stock-based compensation), materials and subcontractors, and
because we have recently begun examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense
and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive and energy and
increase in facility costs due to a lease for additional office space.
In
addition, there was an increase in R&D payroll expenses in first half of 2022 due to the fact that during the first half of 2021
a part of our payroll expenses was capitalized to contract fulfillment asset and was not recognized as expenses in profit
and loss.
We
expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional
research and development employees to the I4.0 domain.
Sales
and Marketing Expenses
Sales
and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment and
certain allocated facility infrastructure costs.
Sales
and marketing expenses for the six months ended June 30, 2022 were $446,000, an increase of $42,000, or 10%, compared to $404,000 for
the six months ended June 30, 2021.
The
increase was primarily due to an increase in payroll expenses (including stock-based compensation) due to the recruitment of a VP Business
Development in Industry 4.0.
We
expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.
General
and Administrative Expenses
General
and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel
in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related
costs, as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services
and insurance costs.
General
and Administrative expenses for the six months ended June 30, 2022 were $2,452,000, an increase of $124,000, or 5%, compared to $2,328,000
for the six months ended June 30, 2021.
The increase
was primarily due to an increase in share based compensation due to new options and RSUs grants, partially offset by a decrease in IP
expenses.
- 21 -
Operating
loss
We
incurred an operating loss of $5,350,000 for the six months ended June 30, 2022, an increase of $1,663,000, or 45%, compared to operating
loss of $3,687,000 for the six months ended June 30, 2021.
The
increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development
and sales and marketing, as described above.
Cash
Flows
The
following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):
Six
month ended June 30,
2022
2021
Cash
used in Operating Activity
(2,398,000
)
(3,054,000
)
Cash
provided by (used in) Investing Activity
1,458,000
(170,000
)
Cash
provided by Financing Activity
-
21,622,000
Operating
Activities
Our
primary uses of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing
costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating
activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.
During
the six months ended June 30, 2022, cash used in operating activities was $2.4 million, consisting of net loss of $5.6 million, partially
offset by a non-cash benefit of $1.5 million, a favorable net change in operating assets and liabilities of $1.3 million and loss from
exchange differences on cash and cash equivalents of $0.3 million. Our non-cash benefit consisted primarily of non-cash charges of $1.5
million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes
in contract liability of $1.4 million.
During
the six months ended June 30, 2021, cash used in operating activities was $3.1 million, consisting of net loss of $3.7 million partially
offset by a non-cash benefit of $0.6 million. Our non-cash benefit consisted primarily of non-cash charges of $0.6 million for stock-based
compensation.
- 22 -
Investing
Activities
For
the six months ended June 30, 2022, net cash flows provided by investing activities was $1,458,000, due to change of $1,500,000 in
short terms deposits partially offset by the purchase of property and equipment.
For
the six months ended June 30, 2021, net cash flows used in investing activities was $170,000, due to the purchase of property and equipment.
Financing
Activities
For
the six months ended June 30, 2021, net cash flows provided by financing activities was $21.6 million, due to proceeds from the issuance
of shares and warrants equivalent to approximately $19.1 million and proceeds from exercise from warrants of approximately $2.5 million.
Comparison
of the three months ended June 30, 2022 and 2021
The
following table summarizes our results of operations for the three months period ended June 30, 2022, and 2021, together with the changes
in those items in dollars and as a percentage:
Three
months ended June 30,
2022
2021
%
Change
Revenues
370,000
274,000
35
%
Cost
of Revenues
561,000
407,000
38
%
Gross
Loss
(191,000
)
(133,000
)
44
%
Research
and development expenses
1,021,000
362,000
182
%
Sales
and marketing expense
203,000
207,000
(2)
%
General
and administrative expenses
1,166,000
1,395,000
(16)
%
Operating
Loss
(2,581,000
)
(2,097,000
)
23
%
Revenues
For
the three months ended June 30, 2022, we generated revenues of $370,000, an increase of $96,000, or 35%, from the three months ended
June 30, 2021.
The increase in revenues was primarily due to the
increase in revenue from our miniature camera solution with the Fortune 500 company due to completion R&D stage and moving
to production stage. Total revenues recorded from o ur miniature camera solution with the
Fortune 500 company during the six months ended June 30, 2022, amounted to approximately $327,000.
We did not record any revenue from our miniature camera solution with the Fortune 500 company during
the three months ended June 30, 2021.
This
increase in revenues was partly offset by the following:
-
Total revenues recorded from A.M. Surgical during the six months ended June 30, 2021, amounted to approximately $200,000. We did not record any revenue from A.M. Surgical during the three months ended June 30, 2022.
-
the decrease of $31,000 d ue to an overall decrease in the sales of the Company’s component products to occasional customers.
Cost
of Revenues
Cost
of revenue is primarily comprised of cost of personnel including warehouse personnel costs, inventory write-downs, certain allocated
facilities and expenses associated with logistics and quality control.
Cost
of revenues for the three months ended June 30, 2022 was $561,000, an increase of $154,000, or 38%, compared to cost of revenues of $407,000
for the three months ended June 30, 2021.
- 23 -
The
increase was primarily due to an increase in materials as a result of an increase in revenues, an increase in payroll expenses due to
stock-based compensation and due to the transition from the R&D stage to the production
stage as described on “Overview” and increase in facility costs due to a lease for additional office space.
Gross
Loss
Gross
loss for the three months ended June 30, 2022 was $191,000, an increase of $58,000, or 44%, compared to gross loss of $133,000 for the
three months ended June 30, 2021.
The
increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.
Research
and Development Expenses
Research
and development efforts are focused on new product development and on developing additional functionality for our new and existing products.
These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for
personnel engaged in research and development functions, consulting and professional fees related to research and development activities,
prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities,
depreciation and other supplies. We expense research and development costs as incurred.
Research
and development expenses for the three months ended June 30, 2022 were $1,021,000, an increase of $659,000, or 182%, compared to $362,000
for the three months ended June 30, 2021.
The
increase was primarily due to an increase in payroll expenses (including stock-based compensation), materials and subcontractors, and
because we have recently begun examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense
and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive and energy and
increase in facility costs due to a lease for additional office space.
We
expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional
research and development employees to the I4.0 domain.
Sales
and Marketing Expenses
Sales
and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment and
certain allocated facility infrastructure costs.
Sales
and marketing expenses for the three months ended June 30, 2022 were $203,000, a decrease of $4,000, or 2%, compared to $207,000 for
the three months ended June 30, 2021.
We
expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.
General
and Administrative Expenses
General
and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel
in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related
costs, as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services
and insurance costs.
General
and Administrative expenses for the three months ended June 30, 2022 were $1,166,000, a decrease of $229,000, or 16%, compared to $1,395,000
for the three months ended June 30, 2021.
The
decrease was primarily due to a decrease in IP expenses.
Operating
loss
We
incurred an operating loss of $2,581,000 for the three months ended June 30, 2022, an increase of $484,000, or 23%, compared to operating
loss of $2,097,000 for the three months ended June 30, 2021.
The
increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development
and sales and marketing, as described above.
- 24 -
Cash
Flows
The
following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):
Three month ended June 30,
2022
2021
Cash used in Operating Activity
(2,174,000 )
(2,280,000 )
Cash provided by (used in) Investing Activity
1,482,000
(53,000 )
Cash provided by Financing Activity
-
11,341,000
Operating
Activities
Our
primary use of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing
costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating
activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.
During
the three months ended June 30, 2022, cash used in operating activities was $2.2 million, consisting of net loss of $2.8 million and
an unfavorable net change in operating assets and liabilities of $0.4 million partially offset by a non-cash benefit of $0.7 million,
and loss from exchange differences on cash and cash equivalents of $0.3 million. Our non-cash benefit consisted primarily of non-cash
charges of $0.7 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash
inflows from changes in inventory of $0.4 million.
Investing
Activities
For
the three months ended June 30, 2022, net cash flows provided by investing activities was $1,482,000, due to change of $1,500,000 in
short terms deposits partially offset by the purchase of property and equipment.
For
the three months ended June 30, 2021, net cash flows used in investing activities was $53,000, due to the purchase of property and equipment.
Financing
Activities
For
the three months ended June 30, 2021, net cash flows provided by financing activities was $11.3 million, due to proceeds from the issuance
of shares and warrants equivalent to approximately $9.6 million and proceeds from exercise from warrants of approximately $1.7 million.
Additional
Cash Requirements
We
plan to continue to invest for long-term growth, and therefore we expect that our expenses will increase. We currently believe that
our existing cash and cash equivalents and short-term deposits will be sufficient to meet our anticipated cash needs for at least the
next 12 months. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research
and development and the scale up process of our I4.0 solutions. We expect to incur significant commercialization expenses related to
product sales, marketing, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating
as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.
We may raise these funds through equity financing, debt financing or other sources, which may result in further dilution in the equity
ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors
to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement
our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan,
we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive
terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.
Liquidity
and Capital Resources
As
of June 30, 2022, we had cash and cash equivalents of $7.3 million and $9.5 million of short-term deposits compared to cash and cash
equivalents $8.6 million and $11 million of short-term deposits as of December 31, 2021. In addition, as of June 30, 2022 we incurred
an accumulated deficit of approximately $20.9 million, compared to $15.3 million as of December 31, 2021.
Our
primary sources of liquidity to date have been from fund raising and warrant exercises.
- 25 -
Off-Balance
Sheet Arrangements
None.
Item
3. Quantitative and Qualitative Disclosures About Market Risk.
As
a smaller reporting company, we are not required to provide the information requested by this Item.
Item
4. Controls and Procedures.
Disclosure
Controls and Procedures
Under
the supervision and with the participation of our management, including our principal executive officer and our principal financial officer,
we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based
on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures
were effective as of the end of the period covered by this report.
No
change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter
ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
- 26 -
PART
II- OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
From
time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management
believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse
effect on our results of operations, financial condition or cash flows.
ITEM
1A. RISK FACTORS.
There
have been no material changes from the information set forth in “Risk Factors” in our
Annual Report on Form 10-K for the fiscal year ended December 31,2021 as filed with the SEC on March 30, 2022.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES
There
have been no unregistered sales of equity securities in addition to the sales provided under Form 8-K as filed with the SEC during the
recent fiscal quarter ended June 30, 2022.
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM
4. MINE SAFETY DISCLOSURE
Not
applicable.
ITEM
5. OTHER INFORMATION
None.
ITEM
6. EXHIBITS.
(a)
The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.
Exhibit
Number
Description
3.1.1
Amended and Restarted Articles of Incorporation, effective as of August 9, 2021 (incorporated by reference to Exhibit 3.1.4 to our Quarterly Report on Form 10-Q filed with the SEC on August 12,2021)
3.2.1
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.2 to our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021).
31.1*
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2*
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32.1**
Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**
Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
Inline
XBRL Instance Document
101.INS
Inline
XBRL Taxonomy Extension Schema Document
101.CAL
Inline
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
Inline
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline
XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover
Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
*
Filed
herewith.
**
Furnished
herewith.
- 27 -
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
August 11, 2022
SCOUTCAM
INC.
By:
/s/
Benad Goldwasser
Name:
Benad
Goldwasser
Title:
Chairman
of the Board
ScoutCam
Inc.
By:
/s/
Tanya Yosef
Name:
Tanya
Yosef
Title:
Chief
Financial Officer
ScoutCam
Inc.
- 28 -
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.